A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma.
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
28
05
2020
accepted:
23
06
2020
pubmed:
2
7
2020
medline:
22
6
2021
entrez:
2
7
2020
Statut:
ppublish
Résumé
Treatment with the Aurora kinase A inhibitor yields often durable disease control, but limited tumor regression, in heavily pretreated patients with unresectable malignant pleural or peritoneal mesothelioma. In a limited sample size, MYC copy-number gain or gene amplification, a candidate predictive biomarker for alisertib, did not correlate with improved response numbers or patient outcomes. Malignant mesothelioma is an aggressive disease for which few effective therapies are available. The Aurora family kinases are critical for mitotic fidelity and highly expressed in mesothelioma, wherein their inhibition leads to growth arrest in vitro. We evaluated the efficacy of alisertib, an Aurora A kinase inhibitor, in relapsed malignant mesothelioma. Twenty-six patients with previously treated, unresectable pleural or peritoneal mesothelioma were enrolled on a single-arm, single-institution phase II trial of alisertib at a dosage of 50 mg twice daily for 7 of every 21 days. The primary endpoint was 4-month disease control rate. Secondary endpoints included overall response rate, progression free survival, overall survival, safety/toxicity, and correlation of endpoints with MYC copy number. Of the 25 evaluable patients treated on study, 8 (32%) experienced 4-month disease control, surpassing the futility endpoint. There were no confirmed partial or complete responses. Median progression-free and overall survival were 2.8 months and 6.3 months, respectively. No associations between MYC copy number and outcomes were observed. Alisertib has modest activity in this unselected malignant mesothelioma population. Several patients achieved durable disease control. Although the study did meet its prespecified futility endpoint, the sponsor elected to close the trial at the interim analysis.
Sections du résumé
LESSONS LEARNED
Treatment with the Aurora kinase A inhibitor yields often durable disease control, but limited tumor regression, in heavily pretreated patients with unresectable malignant pleural or peritoneal mesothelioma. In a limited sample size, MYC copy-number gain or gene amplification, a candidate predictive biomarker for alisertib, did not correlate with improved response numbers or patient outcomes.
BACKGROUND
Malignant mesothelioma is an aggressive disease for which few effective therapies are available. The Aurora family kinases are critical for mitotic fidelity and highly expressed in mesothelioma, wherein their inhibition leads to growth arrest in vitro. We evaluated the efficacy of alisertib, an Aurora A kinase inhibitor, in relapsed malignant mesothelioma.
METHODS
Twenty-six patients with previously treated, unresectable pleural or peritoneal mesothelioma were enrolled on a single-arm, single-institution phase II trial of alisertib at a dosage of 50 mg twice daily for 7 of every 21 days. The primary endpoint was 4-month disease control rate. Secondary endpoints included overall response rate, progression free survival, overall survival, safety/toxicity, and correlation of endpoints with MYC copy number.
RESULTS
Of the 25 evaluable patients treated on study, 8 (32%) experienced 4-month disease control, surpassing the futility endpoint. There were no confirmed partial or complete responses. Median progression-free and overall survival were 2.8 months and 6.3 months, respectively. No associations between MYC copy number and outcomes were observed.
CONCLUSION
Alisertib has modest activity in this unselected malignant mesothelioma population. Several patients achieved durable disease control. Although the study did meet its prespecified futility endpoint, the sponsor elected to close the trial at the interim analysis.
Identifiants
pubmed: 32608142
doi: 10.1634/theoncologist.2020-0610
pmc: PMC7543335
doi:
Substances chimiques
Azepines
0
MLN 8237
0
Pyrimidines
0
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1457-e1463Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
© 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
Références
Lung Cancer. 2010 Dec;70(3):271-9
pubmed: 20371132
Lancet. 2016 Apr 2;387(10026):1405-1414
pubmed: 26719230
Cancer Res. 2006 Mar 15;66(6):2970-9
pubmed: 16540645
Control Clin Trials. 1989 Mar;10(1):1-10
pubmed: 2702835
Nat Med. 2016 Jul;22(7):744-53
pubmed: 27213815
J Thorac Oncol. 2020 Feb;15(2):274-287
pubmed: 31655296
Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1519-25
pubmed: 17394948
Cell. 1995 Apr 7;81(1):95-105
pubmed: 7720077
J Biol Chem. 2001 Dec 7;276(49):46219-24
pubmed: 11551964
Am J Pathol. 2009 Mar;174(3):762-70
pubmed: 19218339
Mol Cell Biol. 2007 Jun;27(12):4513-25
pubmed: 17438137
J Biol Chem. 2003 Dec 19;278(51):51786-95
pubmed: 14523000
J Thorac Oncol. 2014 Jul;9(7):998-1007
pubmed: 24926545
Nat Rev Mol Cell Biol. 2001 Jan;2(1):21-32
pubmed: 11413462